JP2011504474A5 - - Google Patents

Download PDF

Info

Publication number
JP2011504474A5
JP2011504474A5 JP2010534409A JP2010534409A JP2011504474A5 JP 2011504474 A5 JP2011504474 A5 JP 2011504474A5 JP 2010534409 A JP2010534409 A JP 2010534409A JP 2010534409 A JP2010534409 A JP 2010534409A JP 2011504474 A5 JP2011504474 A5 JP 2011504474A5
Authority
JP
Japan
Prior art keywords
use according
disease
medicament
inhibitor
alzheimer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010534409A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011504474A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2008/009880 external-priority patent/WO2009065596A2/en
Publication of JP2011504474A publication Critical patent/JP2011504474A/ja
Publication of JP2011504474A5 publication Critical patent/JP2011504474A5/ja
Pending legal-status Critical Current

Links

JP2010534409A 2007-11-22 2008-11-21 アルツハイマー氏病を治療するためのＭｎｋインヒビターの使用 Pending JP2011504474A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07022695 2007-11-22
PCT/EP2008/009880 WO2009065596A2 (en) 2007-11-22 2008-11-21 Use of mnk inhibitors for the treatment of alzheimer's disease

Publications (2)

Publication Number Publication Date
JP2011504474A JP2011504474A (ja) 2011-02-10
JP2011504474A5 true JP2011504474A5 (enExample) 2011-12-22

Family

ID=40404966

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010534409A Pending JP2011504474A (ja) 2007-11-22 2008-11-21 アルツハイマー氏病を治療するためのＭｎｋインヒビターの使用

Country Status (5)

Country Link
US (1) US20100247517A1 (enExample)
EP (1) EP2219649A2 (enExample)
JP (1) JP2011504474A (enExample)
CA (1) CA2706203A1 (enExample)
WO (1) WO2009065596A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2655799A1 (en) * 2005-06-22 2006-12-28 Develogen Aktiengesellschaft Thienopyrimidines for pharmaceutical compositions
CA2651898A1 (en) * 2006-04-07 2007-10-18 Develogen Aktiengesellschaft Thienopyrimidines having mnk1/mnk2 inhibiting activity for pharmaceutical compositions
EP1889847A1 (en) * 2006-07-10 2008-02-20 DeveloGen Aktiengesellschaft Pyrrolopyrimidines for pharmaceutical compositions
JP2010528647A (ja) * 2007-06-06 2010-08-26 ドマンティス リミテッド ポリペプチド、抗体可変ドメインおよびアンタゴニスト
UY32072A (es) 2008-08-26 2010-03-26 Boehringer Ingelheim Int Tienopirimidinas para composiciones farmacéuticas
JP5575274B2 (ja) * 2010-02-26 2014-08-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 医薬組成物のためのｍｎｋｌ／ｍｎｋ２阻害活性を有する４−［シクロアルキルオキシ（ヘテロ）アリールアミノ］チエノ「２，３−ｄ］ピリミジン
UY33241A (es) * 2010-02-26 2011-09-30 Boehringer Ingelheim Int ?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?.
MX2012009851A (es) * 2010-02-26 2012-09-12 Boehringer Ingelheim Int Tienopirimidinas que contienen un grupo alquilo sustituido para composiciones farmaceuticas.
WO2013012848A1 (en) 2011-07-18 2013-01-24 Merck Patent Gmbh Benzamides
EP3134405B1 (en) 2014-04-25 2019-08-28 Pfizer Inc Heteroaromatic compounds and their use as dopamine d1 ligands
GB201520499D0 (en) * 2015-11-20 2016-01-06 Medical Res Council Technology Compounds
GB201520500D0 (en) * 2015-11-20 2016-01-06 Medical Res Council Technology Compounds
CA3053493A1 (en) 2017-02-14 2018-08-23 Effector Therapeutics, Inc. Piperidine-substituted mnk inhibitors and methods related thereto
CN113286592A (zh) 2018-10-24 2021-08-20 效应治疗股份有限公司 Mnk抑制剂的结晶形式

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW370529B (en) * 1992-12-17 1999-09-21 Pfizer Pyrazolopyrimidines
EP0729758A3 (en) * 1995-03-02 1997-10-29 Pfizer Pyrazolopyrimidines and pyrrolopyrimidines for the treatment of neuronal and other diseases
GB9906566D0 (en) * 1999-03-23 1999-05-19 Zeneca Ltd Chemical compounds
US7419978B2 (en) * 2003-10-22 2008-09-02 Bristol-Myers Squibb Company Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors
WO2005067908A2 (en) * 2004-01-05 2005-07-28 Merz Pharma Gmbh & Co. Kgaa Memantine for the treatment of mild and mild-to-moderate alzheimer’s disease
GB0412467D0 (en) * 2004-06-04 2004-07-07 Astrazeneca Ab Chemical compounds
EP1746099A1 (en) * 2004-12-23 2007-01-24 DeveloGen Aktiengesellschaft Mnk1 or Mnk2 inhibitors
CA2655799A1 (en) * 2005-06-22 2006-12-28 Develogen Aktiengesellschaft Thienopyrimidines for pharmaceutical compositions
WO2007059905A2 (en) * 2005-11-25 2007-05-31 Develogen Aktiengesellschaft Thienopyrimidines treating inflammatory diseases
MX2008012479A (es) * 2006-03-29 2009-08-13 Velacor Therapeutics Pty Ltd Tratamiento de enfermedades neurodegenerativas.
FR2899107B1 (fr) * 2006-03-30 2008-06-13 Neurokin Entpr Unipersonnelle Utilisation de la (s)-roscovitine pour la fabrication d'un medicament
CA2651898A1 (en) * 2006-04-07 2007-10-18 Develogen Aktiengesellschaft Thienopyrimidines having mnk1/mnk2 inhibiting activity for pharmaceutical compositions
US20080107755A1 (en) * 2006-04-24 2008-05-08 Alltech, Inc. Methods and compositions for altering cell function
US20080039450A1 (en) * 2006-06-22 2008-02-14 Jensen Annika J Compounds

Similar Documents

Publication Publication Date Title
JP2011504474A5 (enExample)
JP5657556B2 (ja) α７選択的リガンドを用いる治療
IL191311A (en) Transdermal therapeutic system and its use in the preparation of drugs for the prevention, treatment or delay of the progression of Alzheimer's disease, Parkinson's disease-related dementia and symptoms of traumatic brain injury
HK1199726A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
HK1198619A1 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
PH12012501480A1 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
PH12017502049A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
EP2279727A3 (en) Nanoparticulate aripiprazole formulations
JP2010535801A5 (enExample)
JP2012508734A5 (enExample)
EP2331095A4 (en) CYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF
AR074240A1 (es) Compuesto 3-(4-cloro-2-fluorobencil )-2-metil-n-(5- metil-1h- pirazol-3-il)-8- (morfolinometil)imidazo (1,2-b)piridazin -6-amina o una sal farmaceuticamente aceptable del mismo, su uso para preparar un medicamento util para el tratamiento de trastornos mieloproliferantes cronicos y condiciones asoci
EA201492010A1 (ru) Применение высокой дозы лахинимода для лечения рассеянного склероза
CY1105507T1 (el) Υποκατεστημενες πυραζολο- και θειαζολοπυριμιδινες
JP2021525729A5 (enExample)
RU2013154699A (ru) Сцилло-инозитол для применения в лечении поведенческих и психических расстройств
JP2015500223A5 (enExample)
JP2012531402A5 (enExample)
WO2007096396A3 (en) Methods for treating autoimmune or demyelinating diseases
JP2009178162A5 (enExample)
JP2018529747A5 (enExample)
JP2020527172A5 (enExample)
JP2012511571A5 (enExample)
JP2017511307A5 (enExample)
SI3125876T1 (en) New use of N, N-bis-2-mercaptoethyl isophthalamide